BlueLinx is an example of the type of stock we should be buying Van. Description BlueLinx Holdings Inc., together with its subsidiaries, distributes residential and commercial building products in the United States. It distributes structural products, including plywood, oriented strand board, rebar and remesh, lumber, spruce, and other wood products primarily that are used for structural support and walls in construction projects; and specialty products comprising engineered wood, moulding, siding and trim, cedar, metal, and insulation products. The company also provides a range of value-added services and solutions to its customers and suppliers. It serves dealers, specialty distributors, national home centers, and manufactured housing customers through a network of distribution centers. The company is headquartered in Marietta, Georgia.
Here is what Voss Capital has to say about BlueLinx Holdings Inc. in its Q3 2021 investor letter: "We believe those calling for a peak in housing activity have grown too cautious too soon. Most of the bearish arguments we encounter appear more sentiment based, e.g., prices have come too far too fast. Setting aside this understandably inherent acrophobia-induced caution and focusing more squarely on empirical evidence, the supply/demand picture remains on solid footing thanks to continued record low housing inventory accompanying fresh 30-year lows in single family and multifamily vacancies.6 Furthermore, roughly 2 million more people will turn 35 years old anually over the next five years, as compared to the previous five years. Since 35 is the peak first time home buying age, we believe there will be sustained demand for years to come. Our long portfolio remains heavily geared to entry-level housing related companies, as well as those tied to home remodeling. One of our preferred ways to express this bullish thematic view is through BlueLinx Holdings Inc. (BXC). We knew investors had been bracing for a profit collapse on the back of a fast 73% decline in lumber prices that occurred from May to September, but we had a differentiated view based on the company’s earnings mix that is skewed to Specialty products with less volatile pricing as opposed to purely commoditized framing lumber. The stock continues to be overly discounted based on apathy, ambiguity, and fear over the housing cycle. By our math, even in the unlikely event that BXC’s Structural Products segment produces $0.00 in gross profits over the next year (compared to $187.7M LTM) and their Specialty segment revenue declines 5-10% from here, the company still has sustainable earnings power in excess of $12 per share. At 10x earnings, a modest discount to the company’s long-term P/E ratio despite the balance sheet being deleveraged, the stock still has 63% upside. A more reasonable earnings power estimate is in the $16.50-$19.00 range, which puts the stock under 4x fully taxed net income. Unfortunately, the Board did not pull the trigger on any of their authorized share buyback last quarter before the stock rose 50% after earnings. If they sharpen their pencils anytime soon and buy stock back at this depressed valuation, the normalized EPS number should only move higher."
DID YOU BUY MICHAEL KORS FOR X-MAS-- STILL TIME.... Capri Holdings Limited (CPRI) NYSE - Nasdaq Real Time Price. Currency in USD 63.20+1.51 (+2.45%)<------------ As of 01:04PM EST.
MY GARDEN IS ALIVE-2022 Ideas- Stock #1. Allergan now owned by AbbVie Inc. (ABBV) NYSE - NYSE Delayed Price. Currency in USD 134.41+1.32 (+0.99%) At close: December 27 04:01PM EST 134.55 +0.14 (+0.10%) Pre-Market: 08:43AM EST The chart is breathtaking. It's straight up baby. For a large stock with a Div. what is going on here? I cannot see up close anymore. They have a drop that is sweeping the nation by storm. 1/2 hour after taking you can read up close.. This is farsighted baby! and our first idea for the new year. Nov 26-- $116 Today- $134!!!!!!!! Yield 4.2%! Chart Events Bullishpattern detected Intermediate-term BUY ABBV- AbbVie's subsidiary Allerganhas announced the availability of FDA-approved eye drop, VUITY (pilocarpine HCl ophthalmic solution) 1.25%, by prescription in pharmacies across the US. VUITY is a once-a-day prescription eye drop used for the treatment of age-related blurry near vision or presbyopia in adults.Dec 10, 2021
Common APPS just a few days left... Digital Turbine announces strategic partnership with Google 08:39 APPS, GOOG, GOOGL Digital Turbine (APPS) announced a multi-year strategic partnership with Google (GOOG;GOOGL) that "accelerates Digital Turbine's product and growth strategy to support the Android ecosystem by enabling nearly a billion devices with intelligent app discovery," the company said. Digital Turbine will work with Google Cloud partner SADA to implement Google's enterprise and cloud solutions to enhance and expand globally while broadening growth and monetization solutions for its partners. "For the past 10 years Digital Turbine has helped expand the Android ecosystem with our intelligent app discovery, growth and monetization products supporting many of the leading Android app developers in the market today," said Bill Stone, CEO of Digital Turbine. "We are thrilled to further deepen and expand our partnership with Google. By partnering with Google we are efficiently powering app discovery for nearly a billion Android devices globally while simultaneously expanding our footprint across the Android ecosystem including mobile, TV and connected devices."
Ok love this-! Digital Turbine, Fathom and Veritone named top picks for 2022 at Roth Capital 08:19 APPS, FTHM, VERI 2 of those three are stoney stocks! WTF is FTHM?
I'm almost ready to get into next year mode... Lucira Health price target bumped up to $7 at BofA after COVID test deal 07:24 LHDX BofA analyst Derik de Bruin raised the firm's price target on Lucira Health to $7 from $6.50 after the company announced an amended agreement with Canada's Switch Health Solutions valued at $100M to provide additional at-home molecular COVID-19 diagnostic self-test kits. Noting that COVID-19 testing volumes have trended higher since management gave guidance in early November, de Bruin raised his Q4 and 2022 sales estimates, but he reiterates an Underperform rating on the stock citing the competitive environment, uncertainty over the duration of COVID-19 testing and limited pipeline visibility beyond COVID and flu.